Corfigo, founded with the mission to revolutionize the treatment of persistent atrial fibrillation, is a medical device company focused on developing advanced cryo-ablation technology. Their flagship product, the HeartPad® XLT (Extremely Low Temperature) Cryoablation System, is designed for the ablation of cardiac tissue from an epicardial location while protecting adjacent structures from unintentional injury. This system leverages potent cryothermal energy and a sophisticated delivery mechanism, making it suitable for percutaneous catheter ablation procedures.
Notable figures associated with Corfigo include Deron Siddons, who plays a pivotal role in the company's innovation efforts. The company has achieved significant milestones in the medical device industry, particularly in the development and refinement of cryo-ablation technology for cardiac applications. Corfigo's impact is reflected in its contribution to safer and more effective treatments for atrial fibrillation, potentially improving patient outcomes and advancing the field of cardiac care.
